newsfilter
← Latest News
Business Wire·

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuum NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic